Main text {#Sec1}
=========

Metastasis accounts for 90% of cancer deaths. We developed a mouse model of well-defined multistage tumorigenesis: *RIP-Tag; RIP-tva* to identify metastatic factors \[[@CR1]\]. We identified that the receptor for hyaluronic acid (HA)-mediated motility, isoform B (RHAMM^B^), significantly promotes liver metastasis of pancreatic neuroendocrine tumors (PNET) in *RIP-Tag; RIP-tva* mouse models \[[@CR2]\]. Expression of RHAMM is restricted in normal adult tissues, but is upregulated in cancers \[[@CR3], [@CR4]\]. Increased production of glycosaminoglycan, HA, is correlated with increased migration and invasion in aggressive cancers \[[@CR5]\]. CD44 and RHAMM are two major HA receptors. The roles of CD44 isoforms in cancer have been studied extensively, but the functions of RHAMM isoforms in tumorigenesis are less clear. *RHAMM* encodes 18 exons and alternative splicing generates different isoforms. *RHAMM*^*A*^ includes all 18 exons and *RHAMM*^*B*^ lacks exon 4 (Fig. [1](#Fig1){ref-type="fig"}a). Here we aimed to determine the clinical relevance of *RHAMM*^*A*^ and *RHAMM*^*B*^ isoforms and their functions in pancreatic cancer.Fig. 1RHAMM^B^, but not RHAMM^A^, is upregulated in human PNETs and promotes liver metastasis of mouse PNET cells. **a** Diagram of RHAMM^A^ and RHAMM^B^ proteins. **b** RHAMM is upregulated in 54 of 83 cases (65%) of human PNETs in immunohistochemical staining. Left: Normal pancreas with islets in dashed circle. Middle: RHAMM negative PNET. Right: RHAMM positive PNET. Original magnification: 20X. Scale bar, 50 μm. **c** RNA-seq analysis showed that *RHAMM*^*B*^ is significantly upregulated compared to *RHAMM*^*A*^ in primary human PNETs and liver metastases. The *p* value was calculated using two-way ANOVA followed by Tukey's test. \*\*: *p* \< 0.0001, \*: *p* \< 0.05. Error bars represent standard error of mean. **d** Western blot analysis of human RHAMM in mouse N134 cell line (control), N134-RHAMM^A^ cells, and N134-RHAMM^B^ cells. **e** A total of 1 million N134 cells, N134-RHAMM^A^ cells, or N134-RHAMM^B^ cells were injected into the tail vein of NSG mice (*n* = 5 for each group). Five weeks later, the recipient mice were euthanized to survey for metastatic sites and incidence. Representative liver photos were shown

RHAMM^B^, but not RHAMM^A^, is upregulated in human PNET liver metastases {#Sec2}
-------------------------------------------------------------------------

To investigate RHAMM expression in human PNETs, a tissue microarray consisting of 83 PNETs was immunostained for RHAMM. RHAMM was not detectable in the normal pancreas, while 54 of 83 (65%) PNETs exhibited cytoplasmic staining using an antibody that recognizes common region in RHAMM isoforms (Fig. [1](#Fig1){ref-type="fig"}b). Because isoform-specific RHAMM antibodies were not available, we investigated the mRNA levels of *RHAMM*^*A*^ and *RHAMM*^*B*^ by performing RNA-Seq analysis on 27 primary PNETs and 12 liver metastases, using 89 human islets from NCBI Gene Expression Omnibus database for comparison. Consistent with our immunohistochemical data, normal islets had very low *RHAMM*^*A*^ and *RHAMM*^*B*^ mRNA (Fig. [1](#Fig1){ref-type="fig"}c). *RHAMM*^*B*^ was significantly higher than *RHAMM*^*A*^ in both primary and metastatic PNETs, suggesting that *RHAMM*^*B*^ is the predominant isoform naturally expressed in PNETs. Although *RHAMM*^*A*^ levels in primary tumors were significantly higher than those in normal islets (*p* = 0.0002), *RHAMM*^*A*^ levels in metastatic tumors were not significantly higher than those in normal islets (*p* = 0.8928). The mRNAs of *RHAMM*^*A*^ and *RHAMM*^*B*^ were readily detectable in additional primary PNETs and metastases by RT-qPCR using isoform-specific primers (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A-B).

We compared metastatic potential of RHAMM^A^ to RHAMM^B^ in *RIP-Tag; RIP-tva* models of spontaneous metastasis and tail vein assays \[[@CR1], [@CR2]\]. In contrast to RHAMM^B^, RHAMM^A^ did not promote spontaneous metastasis (Additional file [2](#MOESM2){ref-type="media"}: Table S1). Then, we generated N134 cells overexpressing RHAMM^A^ (N134-RHAMM^A^). N134 is a cell line derived from a PNET of *RIP-Tag; RIP-tva* mouse \[[@CR1]\]. Although there were more RHAMM^A^ than RHAMM^B^ for unknown reasons (Fig. [1](#Fig1){ref-type="fig"}d), only one visible tumor was found in 5 immunodeficient NOD/scid-IL2Rgc knockout (NSG) mice receiving N134-RHAMM^A^ cells after 5 weeks, while all 5 mice receiving N134-RHAMM^B^ cells developed large liver metastases within 5 weeks (Fig. [1](#Fig1){ref-type="fig"}e and Additional file [1](#MOESM1){ref-type="media"}: Figure S2A). To detect micrometastases, we performed immunostaining for synaptophysin, a neuroendocrine marker. Mice receiving N134 cells and N134-RHAMM^A^ cells had an average of 1.8 and 0.6 liver micrometastases, respectively (Additional file [1](#MOESM1){ref-type="media"}: Figure S2B). These data suggested that the unique 15-amino acid-stretch, ESQKNDKDLKILEKE, which is present in RHAMM^A^ but not in RHAMM^B^, inhibits the metastatic function of RHAMM.

RHAMM^B^ is crucial for the metastatic potential of human PNET cell line BON1-TGL {#Sec3}
---------------------------------------------------------------------------------

BON1 is the most utilized human PNET cell line and was established from a peri-pancreatic lymph node in a patient with metastatic PNET. We found that BON1 had much higher expression of *RHAMM*^*B*^ than *RHAMM*^*A*^ as determined by RNA-Seq (Fig. [2](#Fig2){ref-type="fig"}a). We performed shRNA-mediated knockdown of total *RHAMM* to investigate whether this reduces metastasis of BON1-TGL cells, which carry the thymidine kinase/*green fluorescent protein /luciferase* fusion reporter (TGL). Knockdown of *RHAMM* by shRNA was confirmed (Fig. [2](#Fig2){ref-type="fig"}b, c). We used an orthotopic model of PNET liver metastases by injecting cells into the spleen of NSG mice \[[@CR6]\]. Mice receiving control cells developed an average of 82.5 liver metastases after 3 weeks, while mice receiving BON1-TGL-*shRHAMM* cells developed an average of 17 liver metastases with significantly lowered tumor burden (Fig. [2](#Fig2){ref-type="fig"}d-f).Fig. 2RHAMM^B^ is crucial for metastatic potential of human PNET cell line, BON1-TGL. **a** *RHAMM*^*A*^ and *RHAMM*^*B*^ expression in BON1 cell line compared to those in normal islets. **b** *RHAMM*^*A*^ and *RHAMM*^*B*^ knockdown in BON1-TGL cell line by sh*RHAMM* as determined by RT-qPCR analysis. **c** Western blot analysis of RHAMM and tubulin (as a loading control) in BON1-TGL-*shLacZ* cell line and BON1-TGL-*shRHAMM* cell line. **d**-**e** RHAMM knockdown greatly inhibited liver metastasis of BON1-TGL cells. A total of 0.5 million each BON1-TGL-*shLacZ* (control) or BON1-TGL-*shRHAMM* were injected into the spleen of NSG mice (*n* = 4 for each group). After 3 weeks, the recipient mice were euthanized to survey for metastatic sites and incidence. The number of liver macrometastases (**d**) and the tumor burden of liver macrometastases (**e**) were recorded. \*: statistically significantly different (*p* \< 0.05, one-tailed Mann-Whitney U test). Error bars represent standard deviation. **f** Liver sections with hematoxylin and eosin stain. Dashed circles indicate metastases. Original magnification: 10X. Scale bar, 1 mm. **g** RHAMM^B^ overexpression in BON1-TGL-RHAMM^B^ cell line. Western blot analysis of RHAMM and tubulin (as a loading control) are shown. **h** Representative bioluminescent images of NSG mice 4 weeks after injection (upper panel) and their organs (lower panel). A total of 1 million cells was injected into NSG mice via intracardiac injection (*n* = 7). **i** The tumor burden of macrometastases at adrenal glands was documented. \*: statistically significantly different, *p* \< 0.05, t-test

To determine whether even higher RHAMM^B^ levels would further enhance metastasis of BON1-TGL cells, we generated BON1-TGL cells overexpressing RHAMM^B^ (Fig. [2](#Fig2){ref-type="fig"}g). We injected the cells into NSG mice via intracardiac injection. The increased levels of RHAMM^B^ enhanced metastasis of BON1-TGL in mice throughout the mouse body as visualized by bioluminescence imaging and signals from multiple organs were higher in mice receiving BON1-TGL-RHAMM^B^ than those in mice receiving BON1-TGL overexpressing a control vector (Fig. [2](#Fig2){ref-type="fig"}h). Notably, we observed macrometastases at the adrenal glands of mice receiving BON1-TGL-RHAMM^B^, but not in control mice (Fig. [2](#Fig2){ref-type="fig"}i). Taken together, RHAMM^B^ is crucial for PNET metastasis.

*RHAMM*^*B*^ is upregulated in human pancreatic ductal adenocarcinoma (PDAC) and correlates with poor survival {#Sec4}
--------------------------------------------------------------------------------------------------------------

PDAC is the most common pancreatic cancer type. It was shown that total *RHAMM* is upregulated in primary PDAC by RT-qPCR of 14 matched tumors and adjacent normal tissues \[[@CR7]\]. To compare *RHAMM*^*A*^ and *RHAMM*^*B*^ levels in PDAC, we analyzed publicly available The Cancer Genome Atlas (TCGA) datasets. Both *RHAMM*^*A*^ and *RHAMM*^*B*^ were expressed at significantly higher levels in PDAC than in normal pancreatic tissues, and *RHAMM*^*B*^ was substantially higher than *RHAMM*^*A*^ (Fig. [3](#Fig3){ref-type="fig"}a). Survival analysis showed that high *RHAMM* levels were correlated with a worse outcome (Fig. [3](#Fig3){ref-type="fig"}b). Furthermore, patients with high *RHAMM*^*B*^ had inferior survival compared to those with high *RHAMM*^*A*^ (Fig. [3](#Fig3){ref-type="fig"}c, d), suggesting that *RHAMM*^*B*^, but not *RHAMM*^*A*^, is a prognostic factor for survival of PDAC patients. Due to limited information available, we could not perform survival analysis for PNETs.Fig. 3*RHAMM*^*B*^ is upregulated in human pancreatic ductal adenocarcinoma (PDAC) and correlates with poor survival. **a** *RHAMM*^*A*^ and *RHAMM*^*B*^ expression values from TCGA PDAC dataset. *RHAMM*^*A*^: uc003lzf or NM_012484. *RHAMM*^*B*^: uc003lzg or NM_012485. cancer (ca): *n* = 124; control (ctrl): *n* = 4. Bars and error bars represent means and standard errors. **b**-**d** Kaplan-Meier survival analysis of TCGA cohort with 93 PDAC cases. High and low represent the status of the *RHAMM* mRNA expression levels compared to average values. **e** Knockdown efficiency of two EGFR shRNAs. S7 and S9 reduced EGFR protein expression and p-Erk1/2 levels in N134 cells overexpressing RHAMM^B^ by Western blot analysis. α-tubulin was used a loading control. **f** EGFR knockdown greatly inhibited the liver metastasis of N134 cells overexpressing RHAMM^B^. A total of 1 million N134_RHAMM^B^\_shLacZ, N134_RHAMM^B^\_*shEGFR*(S7), or N134_RHAMM^B^\_*shEGFR*(S9) cells were injected into the tail vein of NSG mice (*n* = 5 for each group). At the indicated time points, the recipient mice were euthanized to survey for metastatic sites and incidence. The number of liver macrometastases was recorded. **g** Western blot analysis of p-Erk1/2 and total Erk from N134 overexpressing luciferase (control), and N134_EGFR\*. **h** N134 cells overexpressing luciferase (Luc), N134_EGFR\* (EGFR\*), N134_RHAMM^B^ (RHAMM^B^) were injected into the tail vein of NSG mice (*n* = 5, each group). Five weeks later (for Luc and EGFR\* groups) or when mice were lethargic (for RHAMM^B^), mice were euthanized to survey for metastatic sites and incidence. \*: *p* \< 0.0001, One-way ANOVA and pairwise comparison with Tukey's adjustment

EGFR signaling is required for RHAMM^B^-induced metastasis {#Sec5}
----------------------------------------------------------

EGFR activation is associated with worse survival in many malignancies. Analysis of TCGA PDAC dataset showed a good correlation between *EGFR* and *RHAMM*^*B*^ expression, but not between *EGFR* and *RHAMM*^*A*^ expression (Additional file [1](#MOESM1){ref-type="media"}: Figure S3A-B). We previously showed that EGFR signaling is activated in N134-RHAMM^B^ cells and an EGFR inhibitor, gefitinib, induces apoptosis of N134-RHAMM^B^ cells \[[@CR2]\]. These findings led us to hypothesize that enhanced EGFR signaling involves RHAMM^B^-induced metastasis. To test this hypothesis, we used two different shRNAs targeting mouse *EGFR* (S7 and S9) as well as a control shRNA targeting LacZ (*shLacZ*). sh*EGFR*(S7 and S9) decreased the levels of both EGFR and p-ERK1/2, a downstream target of EGFR signaling, with S7 exhibiting a better knockdown efficiency than S9 (Fig. [3](#Fig3){ref-type="fig"}e).

In tail vein metastasis assays, mice receiving N134-RHAMM^B^-*shLacZ* became lethargic, showing a mean of 29.8 liver macrometastases per mouse within 5 weeks, but mice injected with N134-RHAMM^B^-*shEGFR*(S7) and N134-RHAMM^B^-*shEGFR*(S9) cells did not develop metastases 5 weeks post-injection (Fig. [3](#Fig3){ref-type="fig"}f). An additional cohort of mice injected with N134-RHAMM^B^-*shEGFR*(S7) still did not develop metastases 7 weeks post-injection, and only a mean of 0.5 liver macrometastases appeared in mice injected with N134-RHAMM^B^-*shEGFR*(S9) at this time point (Fig. [3](#Fig3){ref-type="fig"}f).

We investigated whether a constitutively active form of EGFR, EGFR\*, is sufficient to recapitulate RHAMM^B^ activity in metastasis. Five of the 8 *RIP-Tag; RIP-tva* mice receiving RCASBP-*EGFR\** developed pancreatic lymph node metastases (62.5%) and 2 developed liver metastases (25%) (Additional file [2](#MOESM2){ref-type="media"}: Table S1). We generated N134 cells overexpressing EGFR\* (N134-EGFR\*) for experimental metastasis (Fig. [3](#Fig3){ref-type="fig"}g). While no metastasis was found in mice receiving control N134-Luciferase after 6 weeks, an average of 6 liver macrometastases was detected in mice receiving N134-EGFR\* (Fig. [3](#Fig3){ref-type="fig"}h). Although EGFR\* promotes liver metastasis of PNETs in both spontaneous and experimental metastasis mouse models, the degree of metastasis is less than that of RHAMM^B^ (Additional file [2](#MOESM2){ref-type="media"}: Table S1 and Fig. [3](#Fig3){ref-type="fig"}h). Therefore, these EGFR knockdown and EGFR\* overexpression data suggest that activation of EGFR contributes to RHAMM^B^-induced PNET metastasis, but EGFR\* cannot fully recapitulate the metastatic phenotype of RHAMM^B^. Further studies are required to identify signals other than EGFR provided by RHAMM^B^ and to understand whether endogenous levels of RHAMM^A^ activate EGFR signaling.

Conclusion {#Sec6}
==========

We provide evidence that upregulation of RHAMM^B^ is a valuable prognostic marker for pancreatic cancer. We demonstrated that only the shorter isoform RHAMM^B^, but not RHAMM^A^ with 15 extra amino acids encoded by exon 4, is significantly upregulated in PNET and PDAC. RHAMM^B^, but not RHAMM^A^, promotes metastasis in spontaneous and experimental metastasis mouse models of PNET. EGFR signaling is required for RHAMM^B^-induced liver metastasis, but is not sufficient to promote PNET metastasis. *RHAMM*^*B*^, but not *RHAMM*^*A*^, is correlated with inferior survival in PDAC patients.

Additional files
================

 {#Sec7}

Additional file 1:**Figure S1.** RT-qPCR analysis of *RHAMM*^*A*^ (A) and *RHAMM*^*B*^ (B) in 9 primary human PNETs and 3 metastatic PNETs from the livers. **Figure S2.** Unlike RHAMM^B^, RHAMM^A^ did not promote liver metastasis of mouse PNET N134 cell line in a tail vein experimental metastasis assay. (A) The number of liver macrometastases was recorded. (B) Immunohistochemical staining of synaptophysin in the liver sections to reveal the presence of metastatic PNETs. Arrows indicate micrometastases. Original magnification: 10X. Scale bar, 200 μm. **Figure S3.** Correlation between *EGFR* expression and *RHAMM*^*A*^ (A) or *RHAMM*^*B*^ (B) expression in TCGA PDAC dataset (RNA-Seq V2). (PPTX 3371 kb) Additional file 2:**Table S1.** Impact of genes on lymph node and liver metastasis of PNETs in *RIP-Tag; RIP-tva* mice. (DOCX 37 kb) Additional file 3:Supplementary materials and methods. (DOCX 37 kb)
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